The overall data, therefore, indicates that the TMPRSS2-ERG fusion gene and the consequent ERG and CRISP3 overexpression are associated with pathological features related with locally advanced disease in patients with clinically localized prostate cancer. Here, TMPRSS2 is linked to prostate carcinoma.